CSPC Pharmaceutical Group Limited (CVG.F)

China PRC's Covid 19 situation had not improved. There is a rise in number of infections The earlier variety of vaccine appears not to be effective against variants like Omicron and other variants. With the development of the new MRNA vaccine by CSPC China will be able to contain the spread of Covid 19 and other variants like Omicron more effectively and to lift lock down of its cities China had previously been reluctant to use foreign developed MRNA vaccines for reasons known to them. Since the development of the locally manufactured MRNA vaccine (SYS6006) there is no doubt that the Chinese authorities will use it to contain the spread of the pandemic. The population of China is thrice that of North America It is therefore foreseeable that there will be a huge demand for the vaccine developed by CSPC. The share price of CSPC is HKD 7.93 (USD 1.01) per sbare when conpared with other pharmaceutical companies producing MRNA vaccines like Moderna, BioNtech Pfizer it can be seen that CSPC shares are very highly undervalued